Patents by Inventor Todd Parody

Todd Parody has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Insulin-incretin conjugates
    Patent number: 10696726
    Abstract: Disclosed herein are insulin agonist peptides conjugated to a glucagon analog wherein the insulin/glucagon conjugate is targeted to liver tissues upon administration to a patient.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 30, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Todd Parody, Jie Han, Pengyun Li
  • Single chain insulin agonists exhibiting high activity at the insulin receptor
    Patent number: 10233225
    Abstract: Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 19, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Yulia Azriel, Zachary Kaur, Jonathan Meyers, Todd Parody, Yan Zhao
  • Single-chain insulin agonists exhibiting high activity at the insulin receptor
    Patent number: 9458220
    Abstract: Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: October 4, 2016
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Yulia Azriel, Zachary Kaur, Jonathan Meyers, Todd Parody, Yan Zhao
  • Single-chain insulin agonists exhibiting high activity at the insulin receptor
    Patent number: 8940860
    Abstract: Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: January 27, 2015
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Richard D. DiMarchi, Julia Azriel, Zach Kaur, Jonathan Meyers, Todd Parody, Yan Zhao
  • SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR
    Publication number: 20130203665
    Abstract: Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the A1 amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs.
    Type: Application
    Filed: June 16, 2011
    Publication date: August 8, 2013
    Inventors: Richard D. DiMarchi, Julia Azriel, Zach Kaur, Jonathan Meyers, Todd Parody, Yan Zhao